Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation

Opinion statement Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the...

Full description

Saved in:
Bibliographic Details
Published inCurrent treatment options in cardiovascular medicine Vol. 18; no. 4; p. 24
Main Authors Sweis, Rochelle, Biller, José
Format Journal Article
LanguageEnglish
Published New York Springer US 01.04.2016
Springer Nature B.V
Subjects
Anticoagulants
Cardiology
Cerebrovascular Disease and Stroke (N Rost
Drug dosages
Gender differences
Medicine
Medicine & Public Health
Mortality
Section Editor
Stroke
Topical Collection on Cerebrovascular Disease and Stroke
United States > US
NOACs
Stroke
Atrial fibrillation
Vitamin K antagonists
Online AccessGet full text

Cover

More Information
Summary:Opinion statement Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1092-8464
1534-3189
DOI:10.1007/s11936-016-0446-x